Compare MLYS & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MLYS | VINP |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | Brazil |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 638.8M |
| IPO Year | 2023 | 2020 |
| Metric | MLYS | VINP |
|---|---|---|
| Price | $25.91 | $9.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $48.67 | $14.00 |
| AVG Volume (30 Days) | ★ 2.0M | 62.8K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 5.72% |
| EPS Growth | ★ 37.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $18.07 |
| Revenue Next Year | N/A | $12.74 |
| P/E Ratio | ★ N/A | $24.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.59 | $9.20 |
| 52 Week High | $47.65 | $13.61 |
| Indicator | MLYS | VINP |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 42.09 |
| Support Level | $25.40 | $9.66 |
| Resistance Level | $30.85 | $10.88 |
| Average True Range (ATR) | 1.17 | 0.37 |
| MACD | 0.28 | 0.01 |
| Stochastic Oscillator | 81.88 | 19.34 |
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.
Vinci Compass Investments Ltd is an alternative investment platform in Brazil offering asset management, wealth management, and financial advisory services. The company comprises of six business lines i) Global IP&S, (ii) Credit (including public & private credit, opportunistic capital solutions, and agribusiness credit), (iii) Private Equity, (iv) Equities, (v) Real Assets (including real estate, infrastructure and forestry) and (vi) Corporate Advisory.